COLL Q2 2021 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$83M+6.3% YoY

Gross Profit

$50M60.6% margin

Operating Income

$16M19.8% margin

Net Income

$73M87.8% margin

EPS (Diluted)

$1.79

QoQ Revenue Growth

-5.4%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$29M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$714M

Total Liabilities

$461M

Stockholders' Equity

$253M

Cash & Equivalents

$203M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$78M	+6.3%
Gross Profit	$50M	$48M	+3.9%
Operating Income	$16M	$17M	-0.8%
Net Income	$73M	$8M	+804.0%

Revenue Segments

Nucynta

$50M38%

Xtampza

$33M25%

Nucynta Ir

$29M22%

Nucynta Er

$21M16%